Gen-Probe launches colon cancer mutation test kit in Europe
This article was originally published in Clinica
Executive Summary
Gen-Probe has launched its Elucigene KRAS.BRAF kit in Europe. The assay is designed to help tailor treatment for colorectal cancer patients, by detecting seven common mutations in the KRAS gene and the V600E mutation in the BRAF gene. Patients with mutations in these genes do not respond to EGFR inhibitor drugs such as Amgen's Vectibix. Elucigene KRAS.BRAF is a single-tube, PCR-based fluorescent assay designed for simplicity and ease of use. It reduces laboratory workload, analysis time and the potential for sample mix-up, San Diego, California-based Gen-Probe claims. The test is not yet cleared in the US.